The stock is substantially undervalued. With "big pharma" drug companies expected to spend more than $65,000,000,000 in M & A activity in 2013 Keryz is a prime takeover target.
The company's C.E.O. will be presenting tomorrow at the 15th Annual BIO CEO & Investor
Conference. Mr. Bentsur's presentation is scheduled at 2:30 PM ET. A live audio webcast of his presentation will be accessible from the Investor Information page of the company's website